Targeted α-Particle Radiotherapy for Cancer

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Viewpoint is teaming with world-class companies and academic centers to bring its novel product line of therapeutics and complementary diagnostic imaging agents to personalized patient care for metastatic melanoma and neuroendocrine tumors.

Viewpoint Molecular Targeting™ Presents Positive Preclinical Results of VMT01 at the 10th World
Congress of Melanoma

Coralville, IA, April 19, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced additional positive preclinical results from its [212Pb] VMT01 program currently in development for the treatment of metastatic melanoma. These results were presented at the virtual 10th World Congress of
Melanoma held April 15 – 17, 2021.

READ MORE

Viewpoint Molecular Targeting™ Presents Positive Preclinical Results of VMT01 at the 2021 American Association for Cancer (AACR) Annual Meeting

Coralville, IA, April 13, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced positive preclinical results from a study investigating the potential of the melanocortin 1 receptor (MC1R) for targeted drug delivery for the treatment of metastatic melanoma.
READ MORE

Viewpoint Molecular Targeting™ Announces Strategic Partnership with Eichrom Technologies to Accelerate Isotope Production Process Development

Coralville, IA, April 6, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has established a strategic partnership with Eichrom Technologies, LLC (“Eichrom”) to accelerate the automation and scale up of Viewpoint’s isotope production process.
READ MORE

Get in Touch

Join Our Mailing List

Enter your email address below for occasional updates from Viewpoint Molecular Targeting

©2021, Viewpoint Molecular Targeting™.  All Rights Reserved.